The British actor-musician is just about everywhere right now. This week, he's in Berlin for the premiere of Dara Van Dusen's drama with John C. Reilly, and anticipates getting emotional: "It's been ...

The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, Greece, on February 9, 2026. Vaccine manufacturers play a central role in global public health, investing ...

Hims & Hers Health began advertising a $49 Ozempic pill lookalike last week -- then stopped. Novo Nordisk charges $149 for its own Wegovy pills. Lilly charges $299 for Zepbound shots. First, on Friday ...

As the 2026 Winter Olympics get underway in Italy this week, Eli Lilly—a partner of both Team USA and the Milan Cortina Games as a whole—is rolling out a new corporate campaign inspired by the event.

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...

Sales of Lilly's GLP-1 drugs are surging. Management issued a bullish profit forecast. Shares of Eli Lilly (NYSE: LLY) climbed over 10% on Wednesday after the medicine maker delivered a blockbuster ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...

Within the span of 19 hours, weight loss drugmakers Novo Nordisk A/S and Eli Lilly & Co. offered wildly divergent views on where business is headed. After Novo shocked the market by warning sales ...

Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual ...

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has plummeted by 20%. Because the Danish company attributed much of the shortfall to ...

As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage drugs, including a gene therapy from its $1 billion acquisition of Prevail ...